Incorporate T2Direct Diagnostics to rapidly provide targeted treatment for bloodstream infections from common ESKAPE pathogens that can lead to sepsis
Sepsis committees are chartered with introducing new technologies and processes to treat patients with the right therapies more quickly. The inclusion of T2Direct Diagnostics™ in a hospital’s sepsis bundle can enable faster time to targeted therapy, improved patient outcomes, and de-escalation of antimicrobial drug use.
Rapid and accurate diagnostic tools
The T2Direct Diagnostics family of tools provides rapid and accurate results directly from whole blood in 3 to 5 hours. These tools can identify the most serious bacterial and fungal pathogens often not responsive to first-line empiric therapy.
Improved patient outcomes
The T2Bacteria® and T2Candida® Panels are the only FDA-cleared diagnostics that provide species identification for some of the most common and deadly sepsis-causing pathogens – without having to wait 1 to 5 days or more for blood culture results. Early targeted therapy improves patient outcomes; every hour delay of effective antibiotic therapy increases mortality by almost 8% in patients with septic shock.1 A positive T2Bacteria or T2Candida test result may enable rapid targeted treatment and prevent a serious bloodstream infection from progressing to sepsis.
T2Direct Diagnostics: Same-day test results. Improved patient outcomes. Reduced cost.
Faster targeted therapy
Breakthrough speed and accuracy compared to any other diagnostic tool with species ID in 3 to 5 hours
Improved patient outcomes
Potential to reduce hospital and ICU lengths of stay
Decrease time to therapy,2,3,4 de-escalation of unnecessary antifungal use4
Reduction in length of stay for patients in the ICU3
More effective use and better cost management of antimicrobial drugs, with the ability to make rapid adjustments
Reduced cost of sepsis management
Reimbursement for discharged emergency department patients
Economic models demonstrate a 500-bed hospital could save $5.8 million annually and prevent 60% of Candida-related deaths5
Contact us to learn how T2Direct Diagnostics can help your hospital institution!
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.